Oui j’y étais! Plusieurs deuxièmes rencontres sont programmées cette semaines aussi.
Merci de votre réponse rapide … c’est 75% de mon portfolio donc j’essaye de me renseigner au lieu de me fier a des rumeurs.
EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) – Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it is advancing development of a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants. Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have entered into a clinical trial agreement to initiate clinical testing. A Phase 1 clinical trial, expected to be conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), is in development. The Bill & Melinda Gates Foundation (Gates Foundation) is supporting the preclinical evaluation of the vaccine.
Through a license agreement with the La Jolla Institute for Immunology (LJI), one of the leading global organizations dedicated to studying the immune system, Gritstone has access to validated SARS-CoV-2 epitopes that have been identified through LJI’s studies of hundreds of patients recovering from COVID-19. Using these epitopes and the company’s proprietary Gritstone EDGETM and vaccine platform technologies, Gritstone is developing a novel vaccine against COVID-19, containing Spike (similar to first generation vaccines) but also additional viral epitopes that offer good targets for T cell immunity. Gritstone uses both self-amplifying mRNA and adenoviral vectors to deliver the SARS-CoV-2 viral antigens. The vaccine may have pan-SARS/coronavirus potential to protect against future coronavirus pandemics.
Est-ce que ce pourrait être un aperçu de ce qui pourrait arriver à IPA dans les prochaines semaines…
New coronavirus variants seem to be cropping up everywhere. There’s one from the U.K., which is more contagious and already circulating in the U.S. There’s one from South Africa, which is forcing Moderna and Pfizer to reformulate their COVID-19 vaccines and create « booster » shots, just to make sure the vaccines maintain their efficacies.
But for some scientists, the most worrying variant might be the newest one. A variant called P.1, which emerged in Manaus, Brazil
…
The virus finds ways around the vaccine (and our immune system), says Gupta, and so the manufacturers have to reformulate the vaccines (or else we run the risk of getting infected twice).
« We’ve been here before with the flu. We’re having to live with influenza and figure out a way of staying ahead of the virus by making vaccines on a yearly basis, » says Gupta, at the University of Cambridge.
« So I can imagine that we’ll be doing something similar with coronavirus. Eventually we’ll need to design different vaccines that are targeting different parts of the virus — ones that the virus finds harder to change. »
This process is going to cost the world a great deal of money — and take time, Gupta adds. "I don’t think there’s going to be a single solution that just comes along in 2021 that says, ‹ That’s it, we’re done. ›
« The coronavirus is going to cause a long-term disruption. »
Salut Frédérick! Qu’est-ce que cette nouvelle avec Novavax a à voir avec IPA ?
Je voulais souligner le rapprochement avec le CNRC. Montréal va devenir une plaque tournante pour la Bio-Fabrication.
Serait-ce un bought deal pour financer la phase 1… ce qui voudrait dire que les résultats pré cliniques sont assez bons pour aller en phase 1
IPA Increases Previously Announced Bought Deal Offering of Common Shares to $21.7 Million
3 minutes ago, 10:50 PM EST
Via BusinessWire
Stocks mentioned: IPA
Listen
Share
Save
VICTORIA, British Columbia–(BUSINESS WIRE)–IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,616,293 common shares of the Company (the “Common Shares”), at a price to the public of $13.45 per Common Share, less underwriting discounts and commissions, for gross proceeds to the Company of approximately $21.7 million. The closing of the offering is expected to occur on or about February 8, 2021, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as sole book-running manager for the Offering.
The Company also has granted to the underwriter a 30-day option to purchase up to an additional 242,443 Common Shares at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from the Offering for (i) pursuing the Company’s objective of expanding its operations into Good Laboratory Practice and Good Manufacturing Practice-certified; (ii) the development and commercialization of Talem Therapeutics, LLC’s, a wholly owned subsidiary of the Company, internal and partnered therapeutic discovery programs; (iii) investments in employees, partnerships, cloud computing, data curation and analysis to enable further work toward the development of custom algorithms, cloud computing, large-scale sequence data analysis, and expanded access to next-generation sequencing technologies; (iv) the development of its PolyTopeTM approach to the development of innovative therapeutics and vaccines against the COVID-19; and (v) general corporate and working capital purposes.
Pourquoi ne pas avoir attendu les résultats pré-cliniques et une appréciation du SP avant de diluer la compagnie ?
Parce que tu lèves quand tu as du levier (des catalyseurs dans le futur et du cash dans le compte de banque).
Il faut battre le fer quand il est chaud + IPA est loin d’être une aubaine.
Bon commentaire!
H.C. Wainwright doit voir une aubaine dans le prix ou un gros catalyseur futur pour investir 21M!
H.C. Wainwright est le courtier. Ses clients voient un intérêt on dirait oui.